USFDA issues warning to Shilpa Medicare for CGMP violations at Telangana plant ...Middle East

Devdiscourse - Opinion
USFDA issues warning to Shilpa Medicare for CGMP violations at Telangana plant
The US Food and Drug Administration (USFDA) has issued a warning letter to Shilpa Medicare for violating current good manufacturing practice norms at its manufacturing plant in Mahabubnagar district in Telangana. In a letter to company's Managing Director Vishnukant Chaturbhuj Bhutada, the US health regulator said its inspectors, from February 13-20 and February 24-25, 2020, found significant deviations from standard manufacturing practices at company's Unit-IV at Polepally village in Mahabubnagar district.

Hence then, the article about usfda issues warning to shilpa medicare for cgmp violations at telangana plant was published today ( ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( USFDA issues warning to Shilpa Medicare for CGMP violations at Telangana plant )

Apple Storegoogle play

Last updated :

Also on site :



Latest News
before hour & 40 minute